Back to All Events

Endocrinologic and Metabolic Drugs Advisory Committee

The Committee will discuss the safety and efficacy of new drug application (NDA) 210645, for volanesorsen solution for subcutaneous injection, submitted by Akcea Therapeutics, Inc. The proposed indication is as an adjunct to diet for the treatment of patients with familial chylomicronemia syndrome.